Sitagliptin and risk of fractures in type 2 diabetes: Results from the TECOS trial

Diabetes, Obesity and Metabolism

Volumn 19, Issue 1, 2017, Pages 78-86

  Josse, Robert G ^a   Majumdar, Sumit R ^b   Zheng, Yinggan ^c   Adler, Amanda ^d   Bethel, M Angelyn ^e   Buse, John B ^f   Green, Jennifer B ^g   Kaufman, Keith D ^h   Rodbard, Helena W ⁱ   Tankova, Tsvetalina ^j   Westerhout, Cynthia M ^c   Peterson, Eric D ^g   Holman, Rury R ^e   Armstrong, Paul W ^c  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

^d ADDENBROOKE S HOSPITAL   (United Kingdom)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^g DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^h MERCK RESEARCH LABORATORIES   (United States)

ⁱ Endocrine and Metabolic Consultants   (United States)

^j MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

more..

Author keywords

diabetes; DPP 4 inhibitors; fractures; sitagliptin

Indexed keywords

METFORMIN; PLACEBO; SITAGLIPTIN; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; INSULIN;

AGE; AGED; ARM FRACTURE; ARTICLE; CONTROLLED STUDY; DIABETIC NEUROPATHY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; FOLLOW UP; FRACTURE; FRAGILITY FRACTURE; HIP FRACTURE; HUMAN; HYPOGLYCEMIA; INCIDENCE; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; RISK FACTOR; SEX DIFFERENCE; SPINE FRACTURE; BLOOD STORAGE; CAUCASIAN; COMBINATION DRUG THERAPY; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; DOUBLE BLIND PROCEDURE; FRACTURES, BONE; HIP FRACTURES; METABOLISM; MIDDLE AGED; OSTEOPOROTIC FRACTURES; PROPORTIONAL HAZARDS MODEL;

AGE FACTORS; AGED; BLOOD PRESERVATION; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FRACTURES, BONE; HEMOGLOBIN A, GLYCOSYLATED; HIP FRACTURES; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; INSULIN; MALE; METFORMIN; MIDDLE AGED; OSTEOPOROTIC FRACTURES; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SEX FACTORS; SITAGLIPTIN PHOSPHATE;

EID: 84995596092     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12786     Document Type: Article

References (37)

1. Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes—a meta-analysis. Osteoporos Int. 2007;18:427-444.
2. Janghorbani M, Van Dam RM, Willett WC, Hu FB. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol. 2007;166:495-505.
3. Liao CC, Lin CS, Shih CC, et al. Increased risk of fracture and postfracture adverse events in patients with diabetes: two nationwide population-based retrospective cohort studies. Diabetes Care. 2014;37:2246-2252.
4. Shanbhogue VV, Mitchell DM, Rosen CJ, Bouxsein ML. Type 2 diabetes and the skeleton: new insights into sweet bones. Lancet Diabetes Endocrinol. 2016;4:159-173.
5. Schwartz AV, Hillier TA, Sellmeyer DE, et al. Older women with diabetes have a higher risk of falls: a prospective study. Diabetes Care. 2002;25:1749-1754.
6. Schwartz AV, Margolis KL, Sellmeyer DE, et al. Intensive glycemic control is not associated with fractures or falls in the ACCORD randomized trial. Diabetes Care. 2012;35:1525-1531.
7. Gilbert MP, Pratley RE. The impact of diabetes and diabetes medications on bone health. Endocr Rev. 2015;36:194-213.
8. Palermo A, D’Onofrio L, Eastell R, Schwartz AV, Pozzilli P, Napoli N. Oral anti-diabetic drugs and fracture risk, cut to the bone: safe or dangerous? A narrative review. Osteoporos Int. 2015;26:2073-2089.
9. Kahn SE, Zinman B, Lachin JM, et al. Rosiglitazone-associated fractures in type 2 diabetes: an analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care. 2008;31:845-851.
10. Henriksen DB, Alexandersen P, Bjarnason NH, et al. Role of gastrointestinal hormones in postprandial reduction of bone resorption. J Bone Miner Res. 2003;18:2180-2189.
11. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696-1705.
12. Monami M, Dicembrini I, Antenore A, Mannucci E. Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials. Diabetes Care. 2011;34:2474-2476.
13. Mosenzon O, Wei C, Davidson J, et al. Incidence of fractures in patients with type 2 diabetes in the SAVOR-TIMI 53 trial. Diabetes Care. 2015;38:2142-2150.
14. Majumdar SR, Josse RG, Lin M, Eurich DT. Does sitagliptin affect the rate of osteoporotic fractures in type-2 diabetes? Population-based cohort study. J Clin Endocrinol Metab. 2016;101:1963-1969.
15. Driessen JH, van Onzenoort HA, Henry RM, et al. Use of dipeptidyl peptidase-4 inhibitors for type 2 diabetes mellitus and risk of fracture. Bone. 2014;68:124-130.
16. Driessen JH, van Onzenoort HA, Straupe-Linde J, et al. Use of dipeptidyl peptidase 4 inhibitors and fracture risk compared to use of other antihyperglycemic drugs. Pharmacoepidemiol Drug Saf. 2015;24:1017-1025.
17. Green JB, Bethel MA, Paul SK, et al. Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease. Am Heart J. 2013;166:983-989.e7.
18. Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373:232-242.
19. Leslie WD, Rubin MR, Schwartz AV, Kanis JA. Type 2 diabetes and bone. J Bone Miner Res. 2012;27:2231-2237.
20. Giangregorio LM, Leslie WD, Lix LM, et al. FRAX underestimates fracture risk in patients with diabetes. J Bone Miner Res. 2012;27:301-308.
21. Kanis JA, Oden A, Johansson H, Borgstrom F, Strom O, McCloskey E. FRAX and its applications to clinical practice. Bone. 2009;44:734-743.
22. Kim JH, Choi HJ, Ku EJ, et al. Trabecular bone score as an indicator for skeletal deterioration in diabetes. J Clin Endocrinol Metab. 2015;100:475-482.
23. Leslie WD, Aubry-Rozier B, Lamy O, Hans D, Manitoba Bone Density Program. TBS (trabecular bone score) and diabetes-related fracture risk. J Clin Endocrinol Metab. 2013;98:602-609.
24. Lecka-Czernik B. Safety of anti-diabetic therapies on bone. Clin Rev Bone Miner Metab. 2013;11:49-58.
25. Melton LJ 3rd, Leibson CL, Achenbach SJ, Therneau TM, Khosla S. Fracture risk in type 2 diabetes: update of a population-based study. J Bone Miner Res. 2008;23:1334-1342.
26. Su B, Sheng H, Zhang M, et al. Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists’ treatment: a meta-analysis of randomized controlled trials. Endocrine. 2015;48:107-115.
27. Mabilleau G, Mieczkowska A, Chappard D. Use of glucagon-like peptide-1 receptor agonists and bone fractures: a meta-analysis of randomized clinical trials. J Diabetes. 2014;6:260-266.
28. Thrailkill KM, Lumpkin CK Jr, Bunn RC, Kemp SF, Fowlkes JL. Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues. Am J Physiol Endocrinol Metab. 2005;289:E735-E745.
29. Johnston SS, Conner C, Aagren M, Ruiz K, Bouchard J. Association between hypoglycaemic events and fall-related fractures in Medicare-covered patients with type 2 diabetes. Diabetes Obes Metab. 2012;14:634-643.
30. Vestergaard P, Rejnmark L, Mosekilde L. Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia. 2005;48:1292-1299.
31. Nicodemus KK, Folsom AR, Iowa Women’s Health Study. Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women. Diabetes Care. 2001;24:1192-1197.
32. Monami M, Cresci B, Colombini A, et al. Bone fractures and hypoglycemic treatment in type 2 diabetic patients: a case-control study. Diabetes Care. 2008;31:199-203.
33. Colditz GA, Martin P, Stampfer MJ, et al. Validation of questionnaire information on risk factors and disease outcomes in a prospective cohort study of women. Am J Epidemiol. 1986;123:894-900.
34. Ismail AA, O’Neill TW, Cockerill W, et al. Validity of self-report of fractures: results from a prospective study in men and women across Europe. European Prospective Osteoporosis Study Group. Osteoporos Int. 2000;11:248-254.
35. de Liefde II, van der Klift M, de Laet CE, van Daele PL, Hofman A, Pols HA. Bone mineral density and fracture risk in type-2 diabetes mellitus: the Rotterdam Study. Osteoporos Int. 2005;16:1713-1720.
36. Strotmeyer ES, Cauley JA, Schwartz AV, et al. Nontraumatic fracture risk with diabetes mellitus and impaired fasting glucose in older white and black adults: the health, aging, and body composition study. Arch Intern Med. 2005;165:1612-1617.
37. Kendler DL, Bauer DC, Davison KS, et al. Vertebral fractures: clinical importance and management. Am J Med. 2016;129:221.e1–e10.